中西医病证结合抗肝纤维化治疗的策略

doi:10.3736/jcim20040602

Abstract

The strategy for treating liver fibrosis in chronic hepatitis patients includes dispelling the etiological factors, inhibiting the inflammatory reaction, decreasing the sedimentation of extracellular matrix, accelerating the degradation of extracellular matrix, improving the microcirculatory and metabolic disturbance, and ameliorating the complicating diseases, etc. Researchers should pay attention to the liver function indexes in chronic liver disease in evaluating the therapeutic effects of anti-fibrosis. Effective etiological treatment should be considered as the first step in treating liver fibrosis in chronic hepatitis patients, and inhibiting the inflammatory reaction is one of the most important tactics for suppressing the development of fibrosis and for decreasing the incidence rate of liver cancer in chronic hepatitis patients. Treatment based on syndrome differentiation, a dynamic therapy aimed at the holistic pathological state, can improve the pathological state of the disease. It is especially important to take the advantages of the integration of traditional Chinese and western medicine in the clinical diagnostic and therapeutic procedure for increasing the therapeutic effect of live fibrosis.

Key words: liver fibrosis, integration of traditional Chinese and western medicine, therapies

CLC Number:

R575.2

Ping Liu. Strategy for treating liver fibrosis by integration of the disease and its syndromes in traditional Chinese medicine. Journal of Chinese Integrative Medicine, 2004, 2(6): 407-411.

/ / Recommend

Add to citation manager EndNote| Reference Manager|ProCite|BibTeX|RefWorks

URL: http://www.jcimjournal.com/EN/10.3736/jcim20040602

http://www.jcimjournal.com/EN/Y2004/V2/I6/407

trendmd

References 27

[1]	田中荣司. コンセンサス 2004 肝疾患治疗(第1版)[M]. 东京: ァ-クメディァ, 2004,( 第1版):78
[2]	张勘, 曾民德, 范竹萍 , 等. 上海市医学发展基金重点研究项目《肝纤维化非创伤性检测指标及有效干预措施的研究》的组织管理[J]. 肝脏, 2000,5(4):224-226
[3]	马安林, 侯俊兰, 张道明 , 等. 酒精性肝病形成纤维化的危险因素[J]. 中华肝脏病杂志, 2003,11(6):373-374
[4]	Manns MP, McHutchison JG, Gordon SC , et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatictis C: a randomized trial[J]. Lancet, 2001,358(9286):958-965 doi: 10.1016/S0140-6736(01)06102-5
[5]	Fried MW, Schiffman MI, Reddy KR , et al. Peginterferon alfa-2a plus ribavirin for chronic hepatictis C virus infection[J]. N Engl J Med, 2002,347(13):975-982 doi: 10.1056/NEJMoa020047 pmid: 12324553
[6]	周防武昭, 岸本幸广, 川崎宽中 . 肝線維化の治療[A]. 见: 川崎宽中. 肝臟病—今日の診断と最新の治療[M]. 东京: 国际医书出版, 1998. 165-174.
[7]	Ikeda K, Saitoh S, Suzuki Y , et al. Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: a pilot study[J]. Cancer, 1998,82(5):827-835 doi: 10.1002/(ISSN)1097-0142
[8]	Yuen MF, Hui CK, Cheng CC , et al. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications[J]. Hepatology, 2001,34(1):139-145 doi: 10.1016/S0168-8278(01)81383-0
[9]	Dienstag J, Goldin RD, Heathcote EJ , et al. Histological outcome during long-term lamivudine therapy[J]. Gastroenterol, 2003,124(1):105-117 doi: 10.1053/gast.2003.50013 pmid: 12512035
[10]	Kweon YO, Goodman ZD, Dienstag JL , et al. Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B[J]. J Hepatol, 2001,35(6):749-755 doi: 10.1016/S0168-8278(01)00218-5
[11]	谷川久一, 大槻真, 奥平雅彦 , 他.肝胆膵の線維化に関する諸问题[J]. 肝胆膵, 1998,37(3):425-441
[12]	Emond JC, Whitington PF . Selective surgical management of progressive familial intrahepatic cholestasis(Byler's disease)[J]. J Pediatr Surg, 1995,30(12):1635-1641 doi: 10.1016/0022-3468(95)90440-9
[13]	荒濑康司, 池田健次, 熊田博光 . 慢性肝炎に对する强力ネオミノファ–ゲンシ–の效果[J]. 肝胆膵, 2002,44(3):303-310
[14]	蔡雄, 王国俊, 瞿瑶 , 等. 苦参素注射液治疗慢性乙型肝炎临床疗效分析[J]. 第二军医大学学报, 1997,18(1):47-49 doi: 10.1007/BF02951625
[15]	丁岩岩, 斯崇文, 曾争 , 等. 苦参素制剂治疗慢性乙型肝炎的临床试验[J]. 中华内科杂志, 2001,40(12):843-846
[16]	茅益民, 曾民德, 陆伦根 , 等. 氧化苦参碱胶囊治疗慢性病毒性肝炎肝纤维化的随机、双盲、安慰剂对照多中心临床研究(Ⅱ)[[J]. 肝脏, 2002,7(4):222-225 doi: 10.3969/j.issn.1008-1704.2002.04.003
[17]	韩经寰 . 强肝软坚汤治疗肝硬变105例临床观察[J]. 中华医学杂志, 1979,10(10):584-588
[18]	王宝恩, 赵洪涛 . 复方861对肝炎肝纤维化疗效的病理组织学分析[J]. 中华肝脏病杂志, 1997,5(2):77-78
[19]	易毛, 聂凌云, 刘云 , 等. 复方鳖甲软肝片的鉴别研究[J]. 中成药, 2002,24(5):349-352
[20]	刘平, 胡义杨, 刘成 , 等. 扶正化瘀胶囊干预慢性乙型肝炎肝纤维化作用的多中心临床研究[J]. 中西医结合学报, 2003,1(2):89-98 doi: 10.3969/j.issn.1008-861X.2002.01.013
	Liu P, Hu YY, Liu C , et al. Multicenter clinical study about the action of Fuzheng Huayu Capsule against liver fibrosis with chronic hepatitis B[J]. Zhong Xi Yi Jie He Xue Bao, 2003,1(2):89-98
[21]	佘为民, 胡德昌, 周朝晖 , 等. 肝平胶囊治疗慢性乙型肝炎患者肝纤维化的临床研究[J]. 胃肠病学, 2002,7(B11):89-90 doi: 10.3969/j.issn.1008-1704.2002.04.014
[22]	持田智, 藤原研司 . 基础的研究—茵陈蒿汤[J]. 肝胆膵, 2002,44(3):335-339
[23]	山舖昌由. サィトヵィンの制御[J]. 肝胆膵, 2002,44(3):377-389
[24]	Huang W, Zhang J, Moore DD . A traditional herbal medicine enhances bilirubin clearance by activating the nuclear receptor CAR[J]. J Clin Invest, 2004,113(1):137-143 doi: 10.1172/JCI200418385
[25]	刘平, 刘成, 陈高潮 , 等. 扶正化瘀319方治疗慢性乙型肝炎及其对纤维化血清学指标的影响[J]. 中国中西医结合杂志, 1996,16(10):588-592 doi: 10.7661/CJIM.1996.10.588
[26]	张杰, 徐列明 . 中医药治疗实验性肝纤维化作用机制研究进展[J]. 中西医结合学报, 2003,1(2):142-145 doi: 10.3969/j.issn.1009-3427.2003.04.008
	Zhang J, Xu LM . Advances of mechanism research on treatment of experimental liver fibrosis with traditional Chinese medicine[J]. Zhong Xi Yi Jie He Xue Bao, 2003,1(2):142-145
[27]	刘平 . 理论联系实际,基础结合临床, 促进中西医结合肝脏病学科的发展[J]. 中西医结合学报, 2003,1(2):81-83
	Liu P . Development of the integrated TCM hepatology with western medicine[J]. Zhong Xi Yi Jie He Xue Bao, 2003,1(2):81-83

Related Articles 15

[1]	Qing-lan Wang, Yan-yan Tao , Li Shen , Hong-yan Cui , Cheng-hai Liu. Chinese herbal medicine Fuzheng Huayu recipe inhibits liver fibrosis by mediating the transforming growth factor-β1/Smads signaling pathway. Journal of Chinese Integrative Medicine, 2012, 10(5): 561-568.
[2]	Yan-bo Zhu , Hideki Origasa, Xiao-xia Luo, Yang-yang Wang , Jie Di , Lin Lin. Responsiveness of three subjective report of outcome measures for chronic heart failure. Journal of Chinese Integrative Medicine, 2012, 10(12): 1375-1381.
[3]	Hui-min Liu, Xian-bo Wang, Yu-juan Chang, Li-li Gu. Systematic review and meta-analysis of randomized controlled trials of integrative medicine therapy for treatment of chronic severe hepatitis. Journal of Chinese Integrative Medicine, 2012, 10(11): 1211-1228.
[4]	Lei Wang, Li-heng Guo, Jun Zhang, Xu-jie Zhao, Min-zhou Zhang. A study protocol for clinical pathways based on integrative medicine for patients with acute myocardial infarction. Journal of Chinese Integrative Medicine, 2011, 9(7): 725-731.
[5]	Xiao-ning Wang, Qing Tao, Qin Feng, Jing-hua Peng, Ping Liu, Yi-yang Hu. Effects of Chinese herbal medicine Yiguanjian Decoction on collagen metabolism of hepatic tissues in rats with CCI₄-induced liver fibrosis. Journal of Chinese Integrative Medicine, 2011, 9(6): 651-657.
[6]	Li-xin Lang, Xiao-bo Wang, Wei Hou. Successful treatment of adult idiopathic pulmonary hemosiderosis with integrated traditional Chinese and Western medicine: A report of one case. Journal of Chinese Integrative Medicine, 2011, 9(5): 531-532.
[7]	Hong-cai Shang, Jin-ling Huang, Li-wei Han, Ling-peng Pei, Lin Guo, Na Lin, Chang-en Wang . Applications and approved projects on traditional Chinese medicine in National Natural Science Foundation of China in 2010. Journal of Chinese Integrative Medicine, 2011, 9(10): 1045-1050.
[8]	XQ Yue. Towards better understanding the definition of cancerous toxin. Journal of Chinese Integrative Medicine, 2010, 8(9): 829-831.
[9]	the Project Group for Demonstration Study of Syndrome Differentiation Protocol Effect Evaluation of Acute Ischemic Stroke, Yan Huang, Jian-wen Guo. Outcome and safety assessment of an herbal medicine treatment protocol for yin pattern of acute ischemic stroke. Journal of Chinese Integrative Medicine, 2010, 8(5): 417-426.
[10]	Hao Li , Long-tao Liu, Wen-ming Zhao, Jian-gang Liu, Ming-jiang Yao, Yong-xiang Han, Yan-peng Shen, Xing-dong Liu, Li Liu, Xue-mei Wang, Lin-lin Cai, Jie Guan. Traditional Chinese versus integrative treatment in elderly patients with isolated systolic hypertension: A multicenter, randomized, double-blind controlled trial. Journal of Chinese Integrative Medicine, 2010, 8(5): 410-416.
[11]	Ci-an Zhang, Pin-kang Wei, Yong-jin Li. Discussion of the correlation between phlegm and tumor microenvironment. Journal of Chinese Integrative Medicine, 2010, 8(3): 215-219.
[12]	Ni-da Cao, Ai-guang Zhao, Jin-kun Yang. Survival time of advanced gastric cancer patients treated with integrated traditional Chinese and Western medicine therapy. Journal of Chinese Integrative Medicine, 2010, 8(2): 116-120.
[13]	Xue-mei You, Xiao Qin, Zhi-yong Dong, Guan-liang Wang. Integrated traditional Chinese and Western medicine versus Western medicine in treatment of arteriosclerosis obliterans: A systematic review of randomized controlled trials. Journal of Chinese Integrative Medicine, 2010, 8(10): 917-927.
[14]	Hao Li, Long-tao Liu. Considerations about treatment programs of elderly patients with hypertension. Journal of Chinese Integrative Medicine, 2009, 7(7): 607-610.
[15]	Ke-ji Chen, Yue-rong Jiang. Current status and problems in developing clinical guidelines for Chinese medicine and integrative medicine. Journal of Chinese Integrative Medicine, 2009, 7(4): 301-305.

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed

Comments

Recommended 10

[1]	Dong Yang, Yong-ping Du, Qing Shen, Wei Chen, Yan Yu, Guang-lei Chen. Expression of alpha-smooth muscle actin in renal tubulointerstitium in patients with kidney collateral stasis. Journal of Chinese Integrative Medicine, 2008, 6(1): 41-44
[2]	Hai-feng Wei, Bai-liu Ya, Ling Zhao, Cui-fei Ye, Li Zhang, Lin Li. Evaluation of tongue manifestation of blood stasis syndrome and its relationship with blood rheological disorder in a rat model of transient brain ischemia. Journal of Chinese Integrative Medicine, 2008, 6(1): 73-76
[3]	Xi Lin, Jian-ping Liu. Herbal medicines for viral myocarditis. Journal of Chinese Integrative Medicine, 2008, 6(1): 76
[4]	Xi Lin, Jian-ping Liu. Tai chi for treating rheumatoid arthritis. Journal of Chinese Integrative Medicine, 2008, 6(1): 82
[5]	Liang-ping Hu, Hui Gao. Discrimination of errors in statistical analysis of medical papers published in the first issue of 2006 in Journal of Chinese Integrative Medicine. Journal of Chinese Integrative Medicine, 2008, 6(1): 98-106
[6]	Yan-bo Zhu , Qi Wang, Cheng-yu Wu, Guo-ming Pang, Jian-xiong Zhao, Shi-lin Shen, Zhong-yuan Xia , Xue Yan . Logistic regression analysis on relationships between traditional Chinese medicine constitutional types and overweight or obesity. Journal of Chinese Integrative Medicine, 2010, 8(11): 1023-1035
[7]	Wei Xu, Meng Shi, Jian-gang Liu, Cheng-long Wang . Collagen protein expressions in ischemic myocardium of rats with acute myocardial infarction and effects of qi-tonifying, yin-tonifying and blood-activating herbs and detoxifying and blood-activating herbs. Journal of Chinese Integrative Medicine, 2010, 8(11): 1041-1047
[8]	Tao Wang , Feng Qin. Effects of Chinese herbal medicine Xiaoyao Powder on monoamine neurotransmitters in hippocampus of rats with postpartum depression. Journal of Chinese Integrative Medicine, 2010, 8(11): 1075-1079
[9]	Ying Xu , Chang-chun Zeng , Xiu-yu Cai , Rong-ping Guo , Guang Nie , Ying Jin. Chromaticity and optical spectrum colorimetry of the tongue color in different syndromes of primary hepatic carcinoma. Journal of Chinese Integrative Medicine, 2012, 10(11): 1263-1271
[10]	Xiang-ying Mao , Qin Bian , Zi-yin Shen. Analysis of the osteogenetic effects exerted on mesenchymal stem cell strain C3H10T1/2 by icariin via MAPK signaling pathway in vitro. Journal of Chinese Integrative Medicine, 2012, 10(11): 1272-1278

Strategy for treating liver fibrosis by integration of the disease and its syndromes in traditional Chinese medicine

RichHTML

PDF (PC)

Like